Published in Psychopharmacology (Berl) on February 19, 2005
Modeling anxiety using adult zebrafish: a conceptual review. Neuropharmacology (2011) 1.28
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology (2011) 1.06
Psychedelics. Pharmacol Rev (2016) 1.00
Pharmacology of hallucinations: several mechanisms for one single symptom? Biomed Res Int (2014) 0.99
Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology (Berl) (2008) 0.95
Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. Psychopharmacology (Berl) (2008) 0.95
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res (2014) 0.95
Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl) (2008) 0.93
Psilocybin-induced stimulus control in the rat. Pharmacol Biochem Behav (2007) 0.87
An animal model of schizophrenia based on chronic LSD administration: old idea, new results. Neuropharmacology (2011) 0.80
Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. Psychopharmacology (Berl) (2012) 0.80
Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. Psychopharmacology (Berl) (2014) 0.79
Preclinical models of antipsychotic drug action. Int J Neuropsychopharmacol (2013) 0.79
Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia. Neuropharmacology (2014) 0.78
Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology (Berl) (2017) 0.76
Potential serotonin 5-HT(1A) and dopamine D(4) receptor modulation of the discriminative stimulus effects of amphetamine in rats. Behav Pharmacol (2011) 0.76
d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology. Int J Mol Sci (2016) 0.76
Towards a Functional Understanding of PGO Waves. Front Hum Neurosci (2017) 0.75
'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. Bioorg Med Chem (2008) 0.75
Early preclinical studies of discriminable sedative and hallucinogenic drug effects. Psychopharmacology (Berl) (2008) 0.75
A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther (1949) 13.89
Hallucinogens. Pharmacol Ther (2004) 4.01
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) (1996) 2.91
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther (1989) 2.78
[3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol (1982) 2.25
Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse (1987) 2.08
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci (1984) 1.73
The role of serotonin in antipsychotic drug action. Neuropsychopharmacology (1999) 1.49
5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem (2001) 1.43
Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther (2002) 1.25
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem (1990) 1.14
Increasing the selectivity of drug discrimination procedures. Pharmacol Biochem Behav (1999) 0.93
Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol (1983) 0.92
5HT-2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology (Berl) (1990) 0.91
Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur J Pharmacol (1994) 0.90
A proposed animal model for hallucinogens based on LSD's effects on patterns of exploration in rats. Behav Neurosci (1985) 0.88
LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology (Berl) (1995) 0.87
Serotonergic receptor subtypes and hallucinogen-induced stimulus control. Pharmacol Biochem Behav (1999) 0.86
Arylalkylamine drugs of abuse: an overview of drug discrimination studies. Pharmacol Biochem Behav (1999) 0.86
Dissociation of multiple effects of acute LSD on exploratory behavior in rats by ritanserin and propranolol. Psychopharmacology (Berl) (1991) 0.85
Interactions between serotonergic agonists and antagonists in rats trained with LSD as a discriminative stimulus. Pharmacol Biochem Behav (1988) 0.84
The time-dependent stimulus effects of R(-)-2,5-dimethoxy-4-methamphetamine (DOM): implications for drug-induced stimulus control as a method for the study of hallucinogenic agents. Psychopharmacology (Berl) (1995) 0.83
LDS-25 as a discriminative stimulus for response selection by pigeons. Pharmacol Biochem Behav (1980) 0.83
LSD-induced alterations of locomotor patterns and exploration in rats. Psychopharmacology (Berl) (1982) 0.82
Monoaminergic synapses and schizophrenia: 45 years of neuroleptics. J Psychopharmacol (1998) 0.82
A half-century of neurotransmitter research: impact on neurology and psychiatry. Nobel lecture. Biosci Rep (2001) 0.82
5-HT2A/2C receptor agonists potentiate the discriminative cue of (+)-amphetamine in the rat. Neuropharmacology (1997) 0.80
The discriminative stimulus properties of LSD: mechanisms of action. Neuropharmacology (1978) 0.79
Characterization of the discriminative stimulus properties of centrally administered (-)-DOM and LSD. Pharmacol Biochem Behav (2003) 0.79
Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur J Pharmacol (1994) 0.79
A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist. J Pharmacol Exp Ther (1982) 0.79
Hallucinogenic drug research--if so, so what? Symposium summary and commentary. Pharmacol Biochem Behav (1986) 0.79
Differentiation between the stimulus effects of (+)-lysergic acid diethylamide and lisuride using a three-choice, drug discrimination procedure. Psychopharmacology (Berl) (1990) 0.78
The stimulus effects of serotonergic hallucinogens in animals. NIDA Res Monogr (1994) 0.78
Effects of 5HT-1A agonists on locomotor and investigatory behaviors in rats differ from those of hallucinogens. Psychopharmacology (Berl) (1989) 0.78
Cross generalization with LSD and yohimbine in the rat. Eur J Pharmacol (1984) 0.77
A characterization of LSD-antagonist effects of pirenperone in the rat. Neuropharmacology (1983) 0.77
Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats. Psychopharmacology (Berl) (1989) 0.76
Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids. Eur J Pharmacol (1982) 0.76
Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist. J Med Chem (1993) 0.75
Psilocybin as a discriminative stimulus: lack of specificity in an animal behavior model for 'hallucinogens'. Psychopharmacology (Berl) (1982) 0.75
Comparative discriminative stimulus effects of 5-methoxy-N,N-dimethyltryptamine and LSD. Life Sci (1982) 0.75
Differentiation between the stimulus effects of l-5-hydroxytryptophan and LSD. Eur J Pharmacol (1985) 0.75
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
Not all patients want to participate in decision making. A national study of public preferences. J Gen Intern Med (2005) 5.81
The prognostic value of a nomogram for exercise capacity in women. N Engl J Med (2005) 5.03
Loneliness as a specific risk factor for depressive symptoms: cross-sectional and longitudinal analyses. Psychol Aging (2006) 4.63
Exercise capacity and the risk of death in women: the St James Women Take Heart Project. Circulation (2003) 4.19
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology (2004) 3.40
From social structural factors to perceptions of relationship quality and loneliness: the Chicago health, aging, and social relations study. J Gerontol B Psychol Sci Soc Sci (2008) 2.19
Perceived social isolation makes me sad: 5-year cross-lagged analyses of loneliness and depressive symptomatology in the Chicago Health, Aging, and Social Relations Study. Psychol Aging (2010) 2.18
Loneliness predicts reduced physical activity: cross-sectional & longitudinal analyses. Health Psychol (2009) 2.07
Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol (2006) 2.02
Loneliness predicts increased blood pressure: 5-year cross-lagged analyses in middle-aged and older adults. Psychol Aging (2010) 1.93
Heart rate response to exercise stress testing in asymptomatic women: the st. James women take heart project. Circulation (2010) 1.93
Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci (2013) 1.70
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol (2006) 1.61
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol (2010) 1.33
Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther (2002) 1.25
Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther (2002) 1.25
Causes and consequences of kidney loss in patients with nephrolithiasis. Kidney Int (2003) 1.24
Sleep duration and all-cause mortality: a critical review of measurement and associations. Ann Epidemiol (2013) 1.23
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist. J Med Chem (2006) 1.22
A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology (2012) 1.20
Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol (2004) 1.19
Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther (2003) 1.17
1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J Med Chem (2006) 1.13
Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol Pharmacol (2005) 1.12
A marginal structural model analysis for loneliness: implications for intervention trials and clinical practice. J Consult Clin Psychol (2011) 1.09
WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berl) (2006) 1.07
Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. Drug Metab Dispos (2007) 1.06
WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D(4) receptor activation. Behav Pharmacol (2009) 1.01
Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacol Biochem Behav (2007) 1.00
A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. J Neurochem (2003) 0.99
Engineered zinc-binding sites confirm proximity and orientation of transmembrane helices I and III in the human serotonin transporter. Protein Sci (2006) 0.98
Alpha1-adrenergic receptors mediate the locomotor response to systemic administration of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) in rats. Pharmacol Biochem Behav (2007) 0.97
VLDL best predicts aortic root atherosclerosis in LDL receptor deficient mice. J Lipid Res (2008) 0.97
Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Mol Pharmacol (2007) 0.97
Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Mult Scler (2004) 0.97
Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists. J Neurochem (2005) 0.96
Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands. ACS Chem Neurosci (2012) 0.96
Prognostic value of the duke treadmill score in asymptomatic women. Am J Cardiol (2005) 0.94
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res (2007) 0.94
Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl) (2008) 0.93
Mapping the catechol binding site in dopamine D₁ receptors: synthesis and evaluation of two parallel series of bicyclic dopamine analogues. ChemMedChem (2011) 0.92
New victims of current drug laws. Nat Rev Neurosci (2013) 0.92
QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol (2012) 0.92
Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition. J Pharmacol Exp Ther (2008) 0.92
A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor. J Comput Aided Mol Des (2002) 0.91
Hemicraniectomy and durotomy upon deterioration from infarction-related swelling trial: randomized pilot clinical trial. Stroke (2014) 0.89
Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands. J Med Chem (2003) 0.89
8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms. Bioorg Med Chem (2004) 0.89
Serotonin 5-HT(2A) receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism. J Neurochem (2006) 0.87
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res (2007) 0.85
Measuring pseudobulbar affect in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord (2004) 0.84
The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem (2008) 0.84
In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol. Synapse (2002) 0.83
Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling. J Med Chem (2005) 0.83
Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychopharmacology (Berl) (2003) 0.83
3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B. Neurosci Lett (2004) 0.82
The effects of morphine on human articular cartilage of the knee: an in vitro study. Arthroscopy (2002) 0.81
C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem (2006) 0.81
Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes. Bioorg Med Chem (2002) 0.81
Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists. Bioorg Med Chem (2010) 0.81
Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors. Eur Neuropsychopharmacol (2008) 0.81
Synthesis and SAR exploration of dinapsoline analogues. Bioorg Med Chem (2004) 0.81
Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D(1) receptor catechol agonists. Mol Pharmacol (2012) 0.80
A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation. J Anal Toxicol (2006) 0.80
An animal model of schizophrenia based on chronic LSD administration: old idea, new results. Neuropharmacology (2011) 0.80
Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393. Bioorg Med Chem (2011) 0.79
Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT(2A/2C) receptor affinity. Bioorg Med Chem Lett (2002) 0.79
Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacology (Berl) (2002) 0.79
trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT(2) receptor family. Beilstein J Org Chem (2012) 0.79
Treatment of Crohn's disease: the "long" of it. Gastroenterology (2005) 0.78
Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology (Berl) (2012) 0.78
The effect of physician disclosure of financial incentives on trust. Arch Intern Med (2005) 0.78
Structural analysis of the extracellular entrance to the serotonin transporter permeation pathway. J Biol Chem (2010) 0.78
Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters. J Pharmacol Exp Ther (2003) 0.78
The Heffter Research Institute: past and hopeful future. J Psychoactive Drugs (2014) 0.78
Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease. Psychopharmacology (Berl) (2012) 0.78
1-Methylpyridinium-4-(4-phenylmethanethiosulfonate) iodide, MTS-MPP+, a novel scanning cysteine accessibility method (SCAM) reagent for monoamine transporter studies. Bioorg Med Chem (2006) 0.77
Helix XI contributes to the entrance of the serotonin transporter permeation pathway. Protein Sci (2008) 0.77
Neurotoxicity of MDMA (ecstasy): beyond metabolism. Trends Pharmacol Sci (2005) 0.77
A reported "new synthesis of lysergic acid" yields only the derailment product: methyl 5-methoxy-4,5-dihydroindolo[4,3-f,g]quinoline-9-carboxylate. Org Lett (2011) 0.76
Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues. J Med Chem (2011) 0.76
Potential serotonin 5-HT(1A) and dopamine D(4) receptor modulation of the discriminative stimulus effects of amphetamine in rats. Behav Pharmacol (2011) 0.76
An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacol Biochem Behav (2002) 0.76
Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines. Eur J Med Chem (2011) 0.76
A 5-HT(2C) receptor antagonist potentiates a low dose amphetamine-induced conditioned place preference. Neurosci Lett (2011) 0.76
Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand. Bioorg Med Chem (2012) 0.75
'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. Bioorg Med Chem (2008) 0.75
4-aryl-substituted 2,5-dimethoxyphenethylamines: synthesis and serotonin 5-HT(2A) receptor affinities. Chem Biodivers (2009) 0.75
Synthesis and pharmacological evaluation of substituted naphth[1,2,3-de]isoquinolines (dinapsoline analogues) as D1 and D2 dopamine receptor ligands. Bioorg Med Chem (2003) 0.75